Anticoagulation Reversal and Surgical Timing in a Patient with Recent GI Bleed and Acute Subdural Hematoma
A 72-year-old man on apixaban 5 mg twice daily for atrial fibrillation presents with a 6-hour history of progressive confusion and left hemiparesis. CT shows a right acute subdural hematoma (SDH) 12 mm thick with 8 mm midline shift. He had a GI bleed 3 weeks ago (hemoglobin nadir 7.8 g/dL, required transfusion) and is currently on a proton pump inhibitor. His last dose of apixaban was 10 hours ago. He is alert but confused (GCS 14). Creatinine clearance is 45 mL/min. The on-call team must decide on reversal and timing of surgery. There is no on-site neurosurgery; transfer to a tertiary center would take 2 hours by ground.
1. What is the most appropriate strategy for anticoagulation reversal and surgical timing? Justify your choice with reference to the risks of expansion, thromboembolism, and the recent GI bleed.
Read the worked answer
This patient has a symptomatic acute SDH with mass effect and a recent GI bleed, creating competing risks. Apixaban was last taken 10 hours ago; with CrCl 45 mL/min, the half-life is prolonged (~12–15 h), so significant anticoagulant effect persists. Reversal is indicated because of neurologic deterioration and planned surgery. Andexanet alfa is preferred for apixaban reversal when available, but it carries thrombotic risk, particularly in a patient with atrial fibrillation and recent GI bleed. Alternatively, 4-factor prothrombin complex concentrate (PCC) 50 U/kg can be used off-label. Given the recent GI bleed, andexanet may be relatively contraindicated due to thrombosis risk, but the immediate threat is intracranial hemorrhage. A reasonable approach: administer 4F-PCC 50 U/kg and hold further anticoagulation. Do not delay surgery for reversal if the patient is deteriorating; however, surgery in the presence of residual anticoagulation carries bleeding risk. If the patient is neurologically stable (GCS 14), a brief period of reversal (30–60 min) before burr hole evacuation is acceptable. If GCS drops, proceed immediately with surgery while reversal is infusing. Transfer to a tertiary center may be considered if local resources are inadequate, but the 2-hour delay risks further deterioration. The recent GI bleed does not preclude reversal; it increases the risk of rebleeding, so post-reversal monitoring and PPI therapy are essential. Restarting anticoagulation should be deferred for at least 4 weeks, with consideration of left atrial appendage occlusion if anticoagulation is high-risk.
2. How would you modify your management if the patient had instead been on warfarin with an INR of 3.5?
Read the worked answer
For warfarin-associated SDH with INR 3.5 and neurologic symptoms, urgent reversal is indicated. The standard is 4-factor PCC (25–50 U/kg based on INR) plus intravenous vitamin K 10 mg. Fresh frozen plasma is an alternative but is slower and associated with volume overload. Unlike apixaban, warfarin reversal is more predictable and does not carry the same thrombotic concerns as andexanet. Surgery should not be delayed for reversal in a deteriorating patient; PCC can be given in parallel. The recent GI bleed is a relative contraindication to aggressive reversal but the intracranial hemorrhage takes precedence. Postoperatively, restart warfarin only after stabilization and multidisciplinary discussion, considering the GI bleed history.